Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
Priovant reports positive results from the Phase 2 BEACON study of Brepocitinib for cutaneous sarcoidosis, marking a significant step as the first industry-sponsored placebo-controlled trial in this area. The company is now preparing to advance to Phase 3 trials.
Read full storyRecent research published in PubMed outlines the disease mechanisms, diagnostic pathways, and treatment options for sarcoidosis. This comprehensive review enhances understanding of the condition, which may aid in improving patient management.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.